The ABILITY Diabetes Global trial was a multicenter, prospective, open-label randomized controlled trial at 74 sites in 16 countries. 3032 adult patients (≥18 years) with type 1 or type 2 diabetes undergoing PCI for a new coronary lesion in chronic coronary syndrome or NSTE-ACS participated. Patients were randomized to Abluminus DES+ sirolimus-eluting stent (n=1514) or XIENCE everolimus-eluting stent (n=1518). The primary hypothesis was the non-inferiority of Abluminus DES+ versus XIENCE for two co-primary endpoints at 12 months (in the per-protocol population): ischemia-induced target lesion revascularization (margin 2.8%) and target lesion failure (margin 3.0%), defined as cardiovascular death, target artery myocardial infarction, or ischemia-induced target lesion revascularization. Abluminus DES+ was non-inferior to XIENCE resulting in higher rates of ischemia-induced target lesion revascularization and target lesion failure at 12 months. Event rates between months 12 and 24 were similar between groups. 2931 (96.7%) patients completed follow-up until death or 24 months.[1]